Zumutor – Licensing Opportunity for Next Generation Tumor-Directed Immunotherapeutics Harnessing the Power of NK Cells
Zumutor Biologics is a biotechnology company based in Boston, USA, and Bangalore, India, focused on advancing innovative cancer...
top of page
Sage Group News
D-PLEX100 from Polypid for Prevention of Surgical Site Infections - Seeking a US Licensing Partner
Our client, PolyPid Ltd. ( PolyPid - Optimized Therapeutics ; NASDAQ:PYPD) has a patented surgical site infection (SSI) prevention...
Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification
Evecxia deploys 5-hydroxytryptophan, 5-HTP, to achieve Serotonin Synthesis Amplification. 5-HTP amplifies brain serotonin and have shown...
The Sage Group: 30 Years of Successful Bioscience Transactions
London and New York, September 1 2024 - The Sage Group ( www.sagehealthcare.com ), a leading global advisor in the bioscience sector,...
Coagulant’s CT-001 - An Opportunity To License A Novel Factor VIIa with Orphan Drug Designation for the Treatment of Severe Postpartum Hemorrhage (sPPH)
Our client, Coagulant Therapeutics Corporation (CTC), is developing a novel, patented (4 families due to expire 2041-2043 period)...
Partnering/Licensing Opportunity for Tecarfarin, a Phase 3-Ready Oral Anticoagulant for Patients with Certain Orphan Diseases
Cadrenal Therapeutics ( www.cadrenal.com ; NASDAQ: CVKD) is a public U.S. company focused on advancing the development and...
Opportunity to License/Acquire CMX-2043 For Treatment of Traumatic Brain Injury
Ischemix is a privately-held US company developing a novel cytoprotective drug, CMX-2043, for the treatment of acute moderate-to-severe...
BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology Assets
BullFrog’s oncology assets have been acquired through exclusive licenses with Johns Hopkins University (JHU) and include a Phase 2 ready...
bottom of page